New triple therapy could extend lives in stomach cancer
Disease control
Not yet recruiting
This study tests a new drug called TST001 added to standard chemotherapy and immunotherapy for people with advanced stomach or gastroesophageal junction cancer that has not been treated before. The goal is to see if the combination helps control the tumor longer and improves surv…
Phase: PHASE3 • Sponsor: Suzhou Transcenta Therapeutics Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC